Ependymomas rarely show p53 gene alteration, and the tumorigenic mechanism of ependymomas still remains to be elucidated. We investigated the amplification and overexpression of mdm2 gene, whose product (MDM2) is considered to be one of the major cellular regulators of p53-mediated growth control, in 26 specimens of ependymomas obtained from 20 patients. The majority of the ependymomatous samples (96%) showed at least focal immunopositivity for MDM2; however, only 8% of the samples were immunopositive for p53. mdm2 gene amplification was detected in 35% of the samples by differential polymerase chain reaction, all of which overexpressed MDM2. These results suggest that the amplification and/or overexpression of mdm2 may be one of the major molecular events occurring in the tumorigenesis of ependymomas.
Relatively few studies have focused on the molecular biology of ependymomas in comparison to astrocytic tumors (1) . In contrast to astrocytomas, p53 gene aberration is rarely detected in ependymomas (2) (3) (4) , although a germline mutation has been described in one patient with anaplastic ependymoma (5, 6) . The findings therefore indicate the existence of tumorigenic mechanisms of ependymomas that escape from normal p53-related cell cycle regulation.
Oncogene mdm2, localized to chromosome 12q13-14 (7), was originally cloned as a highly amplified gene from spontaneously transformed BALB/c 3T3 cell lines (8) . The mdm2 gene product (MDM2) binds to p53 protein and inactivates its transactivating capability and is thus believed to act as a cellular regulator of the p53 protein. When overexpressed, MDM2 is capable of increasing the tumorigenic potential of NIH3T3 cells (9) . Furthermore, mdm2 has been reported to be amplified and/or overexpressed in a variety of human neoplasms, such as sarcomas (7, 10 -13) , lymphomas (14, 15) , breast cancers (16, 17) , lung cancers (18) , and testicular germ cell tumors (19) .
Regarding neuroepithelial tumors, Newcomb and colleagues (20, 21) failed to detect mdm2 amplification in any grade of astrocytomas. However, Reifenberger et al. (22, 23) reported that up to 10% of glioblastomas showed mdm2 amplification, and these samples lacked p53 mutations. On the other hand, MDM2 overexpression in astrocytic tumors has been detected in 29% of low-grade astrocytomas, 13 to 43% of anaplastic astrocytoma, and 46 to 59% of glioblastomas (21, 24, 25) . Recently, Biernat et al. (26) described that mdm2 was amplified and/or overexpressed preferentially in primary glioblastomas, which typically lack p53 mutations. Reifenberger et al. (22) and Tong et al. (27) also tested ependymal tumors, and both of them mentioned that almost no mdm2 amplification was detected. They did not, however, study the MDM2 protein expression. As discussed in the previous studies of glioblastomas (26) , as well as those of lymphomas (14, 15) , MDM2 was found to be overexpressed in some types of neoplasms without mdm2 gene amplification.
These previous findings prompted us to investigate the amplification and expression of the mdm2 gene in various subtypes of ependymomas in an extended series. In the current study, we screened biopsied ependymomatous samples for mdm2 gene amplification by differential polymerase chain reaction (PCR) and for its overexpression by an immunohistochemical analysis. We discuss the implications of our findings in the tumorigenic mechanisms of ependymomas.
MATERIALS AND METHODS

Ependymomatous Samples
Twenty-six ependymomatous specimens from 20 patients were obtained at surgery. Of these, six specimens were recurrent tumors sampled from four patients. The specimens were immediately immersed in 10% buffered formalin and were fixed overnight. They were then embedded in paraffin. The sections were routinely stained with hematoxylin and eosin. According to the revised World Health Organization classification (28) , the specimens included 4 samples of myxopapillary variant taken from 2 patients, 13 samples of common ependymoma from 11 patients, and 9 samples of anaplastic variant from 7 patients. The patients' age and sex, the location of the tumor, and the histology are summarized in Table 1 .
Immunohistochemistry
Anti-MDM2 monoclonal antibody (mAb) (clone Ab1) and anti-p53 mAb (clone Pab1801) were purchased from Calbiochem (La Jolla, CA) and Novocastra (Newcastle, UK), respectively. Immunohistochemical analysis for MDM2 and p53 were carried out by biotin-streptavidin method as described elsewhere (29) . Briefly, the sections were dewaxed and incubated in 0.3% H 2 O 2 /methanol for 30 min, followed by antigen retrieval by autoclaving in 10 mM citrate buffer pH 6.0 at 120°C for 10 min. After being washed in Tris-HCl buffer (TB) pH 7.6, the sections were incubated with Ab1 (1:10) or Pab1801 (1:20) at 4°C overnight. The sections were then washed in TB and incubated with biotinylated antimouse immunoglobulin (Amersham, Buckinghamshire, UK; 1:200) for 60 min. After being washed in TB, the sections were incubated with horseradish peroxidase-conjugated streptavidin (Amersham; 1:300) for 30 min. The sections were washed in TB, and the reaction products were visualized with diaminobenzidine. In both MDM2 and p53 immunostaining, nuclear staining was judged as positive. We regarded weak staining as positive and indicative of an overexpression of proteins, because both MDM2 and p53 are hardly detected immunohistochemically in mature tissue specimens under normal cell cycle regulation because of their short halflife. We classified the immunopositivity into 2ϩ (more than 50% of cells are positive), ϩ (fewer than 50% of cells are positive), Ϯ (only a few positive cells), and Ϫ (no positive cells). In cases of a heterogeneous distribution of the labeled nuclei, we assessed the immunopositivity in the area with the highest density of stained nuclei.
Differential PCR
DNA was extracted as previously described (30) from the histologically verified, paraffin-embedded 
RESULTS
Immunohistochemistry
By MDM2 immunohistochemistry, 21 specimens (81%) showed 2ϩ, 4 (15%) showed ϩ, and 1 (4%) showed Ϯ. Thus, the majority of specimens showed at least focal immunopositivity for MDM2 (Fig. 1) . Positive nuclei showed variable staining intensity.
The immunopositivity did not correlate with the anaplastic features described in the World Health Organization classification (28); however, it was interesting to note that both cases of myxopapillary ependymoma showed immunopositivity to MDM2 (Fig. 1B) . One exception was a unique case of anaplastic ependymoma, Case A2, which showed the features of clear cell ependymoma intermingled with foci with increased cellularity, prominent mitotic figures, and apoptosis, thus indicating focal anaplastic transformation (Fig. 2C ). This case demonstrated MDM2 immunopositivity preferentially in the anaplastic foci (Fig. 2D ), whereas only a small population of the tumor cells were stained in the less cellular, clear cell ependymoma sites ( Fig. 2A, B) .
Only two specimens (8%, corresponding to 10% of the cases) showed immunopositivity for p53 (one 2ϩ sample and one ϩ sample). Both p53-positive specimens were also MDM2 positive, whereas most of the MDM2-positive specimens (96%, corresponding to 89% of the MDM2-positive cases) were negative for p53 (Table 1) . Both MDM2 and p53 immunostaining tended to show a relatively intense positivity in cells adjoining necrotic foci, probably secondary to ischemia (32) . We therefore evaluated the overall positivity of each section to the exclusion of such epigenetic events in the perinecrotic areas.
Differential PCR
None of the 21 nontumoral DNA samples showed mdm2 amplification (mdm2/DR2 ratio ranging from 0.84 to 1.06). In ependymomatous samples, mdm2 amplification was detected in nine specimens (35%), seven of which were common ependymomas from six cases and two of which were anaplastic ones from the recurrent samples of the same case (sample A3Ј, A3Љ). The myxopapillary type did not show mdm2 amplification. Except for case A3, all patients were adults and had common ependymomas. A representative gel image is shown in Figure 3 . All nine specimens showed immunopositivity for MDM2 (Table 1) .
DISCUSSION
The mdm2 gene is transactivated by p53 protein, and, conversely, MDM2 binds to the p53 protein and inhibits its transactivating capability, thus forming a negative-feedback loop between the molecules (33, 34) . In addition, recent reports have demonstrated that MDM2 promotes the rapid degradation of p53 protein (35, 36) . MDM2 is therefore believed to act as a cellular regulator of p53-mediated growth control.
In our study, the majority of the ependymomatous specimens showed at least focal immunopositivity for MDM2, whereas only two specimens (8%) showed immunopositivity for p53. Furthermore, mdm2 gene amplification was detected in up to 35% of the 26 surgical specimens. These findings are consistent with previous reports describing that ependymomas rarely show p53 gene mutations (2) (3) (4) and that neoplasms with mdm2 amplification typically lack p53 mutations (12, 22) . The immunohistochemical findings are in contrast to those reported in glioblastomas by Newcomb et al. (21) in that up to 20 of the 80 glioblastomatous samples overexpressed both MDM2 and p53. The interaction of MDM2 and p53 may be differently altered in the oncogenesis of different types of tumor.
The frequency of mdm2 amplification was much higher in ependymomas than for that reported in glioblastomas (22, 23, 26) , as well as our personal experience regarding glioblastomas (unpublished data); it was approximately 10%. In addition, mdm2 amplification tended to be detected in adult patients, whereas only one childhood case (Case A3) showed mdm2 amplification in recurrent samples. Whether this observation is due to a different cause between pediatric and adult ependymoma awaits further investigation.
Two cases, C5 and A3, showed different results in differential PCR between the primary samples and the recurrent ones. Case C5 initially showed mdm2 amplification; however, the recurrent sample did not. Case A3 showed mdm2 amplification only in the two recurrent samples. Although we cannot exclude the possibility of biologic changes occurring in the tumors after the initial operation, other possible explanations could be proposed. The behavior of MDM2 is not equal in individual tumor cells even in the same section, and immunopositivity does not always correlate with gene amplification. Sample C5Ј showed less population of the stained nuclei than C5 did (Table 1) . Thus, the intensity of nuclear staining for MDM2 seems to reflect indirectly the degree of gene amplification, because in Cases C5 and A3, the samples that were negative for mdm2 amplification were obviously more weakly stained than those positive for the gene amplification. The results of differential PCR should therefore be interpreted as a characteristic of the predominant population of tumor cells in each sample examined.
The immunohistochemical findings in one anaplastic ependymoma (A2) seem to suggest a potential role of MDM2 in the anaplastic transformation; however, the overall results indicate that in ependymomas, mdm2 amplification and/or overexpression is not generally implicated in the development of anaplastic histologic features described in the World Health Organization classification (28) .
In the present study, MDM2 immunopositivity was detected more frequently than mdm2 amplification (96% versus 35%). This finding suggests the existence of a mechanism of MDM2 overexpression other than gene amplification in ependymomas, as has been suggested in astrocytomas (21) and other neoplasms, such as enhanced transcription (37) and enhanced translation (38) . A dilution effect caused by the heterogeneity of the tumor tissue may also result in an underestimation of mdm2/ DR2 ratio (Table 1) .
Our results contrast with those described by Reifenberger et al. (22) as well as Tong et al. (27) in which almost no mdm2 amplification was detected in ependymomas. The former used Southern hybridization, whereas the latter performed differential PCR using DNA extracted from paraffin sections, as we did in the present study. Although we chose a cutoff value of mdm2/DR2 intensity ratio more strictly than Tong et al. did, we detected mdm2 amplification more frequently among our cases. The reason for this discrepancy is uncertain. However, we assume that high frequency in MDM2 overexpression may, at least in part, result from the gene amplification.
p73 tumor suppressor protein, a p53 homologue that shares structural and functional homology with p53 protein (39, 40) , also binds MDM2 (41-44). Loiseau et al. (45) recently stated that p73 was transcriptionally overexpressed in ependymomas. Although MDM2 does not promote the degradation of p73 (41) (42) (43) (44) , the functional significance of MDM2-p73 interaction in the tumorigenesis has yet to be determined (42) (43) (44) .
Further investigation is therefore necessary to elucidate the relevance of mdm2 gene amplification and overexpression to the oncogenesis of ependymomas; however, this current study demonstrates that a considerable number of ependymomas are clearly associated with this genotypic and/or phenotypic change.
